Increased transmissibility of the B.1.1.7 SARS-CoV-2 variant: Evidence from contact tracing data in Oslo, January to February 2021

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This project was funded by the Norwegian Research Council, project no. 312721 and 237718 and by Nordforsk project no. 105572.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The contact tracing data analysis was done following the data processor agreement between the Norwegian Institute of Public Health and Oslo Municipality, fulfilling Article 28 no. 3 of the EU regulation 2016/679 (GDPR) of 27 April 2016 and the Act on the processing of personal data of 15 June 2018 no. 38 and associated regulations (Privacy Regulations). The study concerns national health preparedness, and the role of the Norwegian Institute of Public Health is specified in the Health Preparedness Act and the Infection Control Act.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes